Tilray Brands TLRY
NASDAQ TLRY
$4.57 -0.26 (-5.28%)
At close: Aug 20, 2026 · 2:06 PM UTC

Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026)

Tilray Brands' (TLRY) quarterly Net Income towards Common Stockholders came in at -$29.6 million in Q2 2026, up 96.73% YoY from -$15.1 million in Q2 2025, and down 17.45% on a QoQ basis from -$25.2 million in Q1 2026.

Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Tilray Brands (TLRY) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$29.6 million in Q2 2026.

  • Quarterly Net Income towards Common Stockholders rose 96.73% year-over-year to -$29.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$96.9 million (up 94.67% YoY) and the FY2026 annual result came in at -$96.9 million, up 94.67% from the prior year.
  • Net Income towards Common Stockholders slipped to -$29.6 million in Q2 2026, from -$25.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $177.5 million in Q2 2023 to a low of -$1.2 billion in Q1 2023.
  • A 5-year average of -$200.1 million and a median of -$51.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 147.75% — and 2025, when it tumbled 9797.92%.
  • Tracing TLRY's Net Income towards Common Stockholders over 5 years: stood at -$85.1 million in 2022, then jumped by 45.71% to -$46.2 million in 2023, then sank by 84.65% to -$85.3 million in 2024, then jumped by 48.98% to -$43.5 million in 2025, then jumped by 31.89% to -$29.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$29.6 million (Q2 2026), -$25.2 million (Q1 2026), and -$43.5 million (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.89 Bn 42.93 Bn - -
2 Teva Pharmaceutical Industries 42.98 Bn 39.33 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.54 Bn 29.86 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.61 Bn 22.81 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.15 Bn 19.48 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.56 Bn 15.17 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 11.74 Bn 11.21 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.95 Bn - -
10 Tilray Brands 512.75 Mn 278.12 Mn 90.52 Mn -29.64 Mn

Historic Data

Download Data
DateValue
May 31, 2026 -29.64 Mn
Feb 28, 2026 -25.23 Mn
Nov 30, 2025 -43.51 Mn
Aug 31, 2025 1.51 Mn
May 31, 2025 -905.20 Mn
Feb 28, 2025 -793.53 Mn
Nov 30, 2024 -85.28 Mn
Aug 31, 2024 -34.65 Mn
May 31, 2024 9.33 Mn
Feb 29, 2024 -104.98 Mn
Nov 30, 2023 -46.18 Mn
Aug 31, 2023 -55.86 Mn
May 31, 2023 177.54 Mn
Feb 28, 2023 -1.20 Bn
Nov 30, 2022 -85.06 Mn
Aug 31, 2022 -65.79 Mn
May 31, 2022 -371.80 Mn
Feb 28, 2022 52.48 Mn
Nov 30, 2021 5.80 Mn
Aug 31, 2021 -34.60 Mn